Khiron Life Sciences has shared an update on its cultivation and production operations near Ibague, Colombia, where it has achieved expanded analysis, extraction and purification capabilities across its cultivation facility.
"Khiron currently owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America," the team with the company explains. "Building on the completion of the facility announced on June 2, 2019, the state-of-the-art, 14,000 square foot GMP and ISO 17025 compliant lab now includes full capabilities in the following:
- Ultra-high and High performance liquid chromatography technology, gas chromatography technology, microbiology testing, and heavy metals for testing flower and extract samples –Through the use of these in-house techniques, Khiron says they can quickly and accurately analyze samples, identify active cannabis components, and ensure that products are extracted and purified to meet local regulations on THC and CBD concentrations.
- Stability testing – Stability tests provide evidence on how cannabis products vary over a given time period and under the influence of environmental factors. According to the company, Khiron currently has robust stability testing capacities in place, with studies designed to evaluate and ensure the quality, safety and efficacy of its products, across various stages of extraction, as well as final product. In Colombia, stability data is needed to receive quotas for the production and domestic commercialization of THC extracts. As part of the Company's commitment to high quality standards, stability testing for extracts and final products are necessary before shipping product to consumers.
- Vertical integration – Leveraging the Company's cultivation, extraction and purification capabilities, Khiron has the ability to manage all stages of cannabis production, from soil to flower to extract, entirely within its own facility. Its vertically integrated capabilities serve to maximize efficiency and reliability across the cannabis supply chain, allowing the Company to streamline operations as it moves towards the sale and distribution of its products.
Alvaro Torres, Khiron CEO and Director, stated, "With advanced analysis, extraction and purification capabilities in place, the company has performed the analytical and stability tests required by the authorities to launch medical products and we remain on track for full commercialization of the grow site, anticipated in Q3 2019. Our significant investment in the Company's Ibague facility, primarily to target a market of 6 million patients in Colombia, ensures Khiron remains focused on its core strategy to serve the domestic market in Latin America."
"Through scalable and flexible operations, the Company has designed its cultivation capabilities to work within the most up-to-date country quota to meet domestic demand, including to serve more than 119,000 patients at the Company's IILANS clinics. Based on the total allocation to the country, the Government of Colombia allocates annual quotas reflecting the operational plan and production estimates as outlined in the licence submissions, with the ability to request additional capacity to meet market demands. Country production quotas for 2020 will be announced by the INCB in January 2020."
For more information:
Khiron Life Sciences Corp.